Merck NEWS US finds COVID-19 Vaccine AstraZeneca safe and effective

2021-03-27 - 2021-03

An analysis of results from 20,000 vaccinnees shows AstraZeneca’s vaccine completely prevents severe or critical COVID-19 and hospitalisation. Results from a large clinical trial in the United States and South America indicate that the COVID-19 Vaccine AstraZeneca is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalisation. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns, including with thromboembolic events, related to the vaccine. With regards to thrombosis and cerebral venous sinus thrombosis (CVST) the DSMB found no increased risk of these conditions in vaccinated participants. The analysis is based on results from 32,449 adult participants enrolled in a placebo-controlled trial (NCT04516746) being conducted across 88 sites in the US, Chile and Peru. One participant received a placebo for every two participants who received the vaccine, therefore approximately 20,000 people received two doses the investigational vaccine four weeks apart.

Brochure Form

Abstracts enquiry

Registration enquiry

Contact Enquiry

Phone

WhatsApp

Useful Links

News

Merck NEWS US finds COVID-19 Vaccine AstraZeneca safe and effective

Newsletter

Brochure

Pharmaceutics and Drug Safety

Brochure Form

Merck NEWS US finds COVID-19 Vaccine AstraZeneca safe and effective